China'S Bio Medical Technology Enterprises Are Popular. Two Companies Are Listed In The United States Within A Week.

Following the burning of stone medicine, a few days ago, the cancer precision medical company also completed the remote listing ceremony. It was officially listed on the Nasdaq Stock Exchange in New York, the stock code is GTH, the issue price is $16, and the financing scale before green shoes is US $260 million. It has become the largest cancer precision medical company listed in the history of the world (according to green shoes).

In fact, Rui Xing incident and trade frictions had cast a shadow on the stock market in the US. However, the following companies such as Jinshan Yun and Nanjing legend have successfully landed on NASDAQ. In this regard, the founder and CEO Wang Sizhen of Pan son, in an interview with the twenty-first Century economic news reporter, said that politics is politics and capital is capital. From the perspective of industry preference, it is clear that biotechnology in China or China's medical industry is being sought after by capital.

From the perspective of the growth of Pan born children, the past few years have developed rapidly and landed in the capital market in a relatively short time. Wang Sizhen explained that it benefited from new breakthroughs in genomics technology, and also benefited from China's big industrial environment and the development of China's economy. "In the past three to five years, not only in China, but also in the global era of genomics development."

Wang Sizhen also told reporters in twenty-first Century economic report, the future does not rule out the possibility of the listing of the science and technology board. "In fact, we have maintained communication with domestic capital market regulators. We also see that the whole domestic capital market regulation policy is gradually opening up. In the future development, we will certainly pay close attention to domestic capital market opportunities. As a Chinese company, there should be opportunities. "

Bio Medical enterprises are popular

"To be listed on NASDAQ is to enhance the whole pan brand and enhance global influence. Our successful listing will also help the world's most important capital market in the world's biomedicine to truly recognize the rise of Chinese biotechnology companies, not to say that China will be good because of the big market." Wang Sizhen told reporters on twenty-first Century economic report.

In the prospectus, the majority of the fund-raising funds will mainly be used for cancer translational medicine research, including diagnostic technology platform optimization, IVD product registration and early screening technology research and development. Wang Sizhen said that listing in the United States will greatly help the world to attract top talent, cooperate with frontier innovation companies and continue refinancing in the course of development.

"After the listing is funded, we will focus on expanding the original research technology, including diagnostics, online and so on. There is still a long way to go for accurate diagnosis, early screening and molecular detection technology based on genomics. We need not only learn from American companies and become more internationalized, but also make good use of China's sample advantages to make technological innovations. Wang Sizhen said.

According to the industry analysis, listing on NASDAQ means that it is necessary to accept professional and choosy investors, including biotechnology and medical companies listed in the United States, such as storied company, pan son, etc., which shows investors' recognition of their technology development and commercialization and the prospect of China's market.

Wang Sizhen analyzed that China's new generation of biotechnology companies, like many American companies, has the world's leading technology and product innovation capability. Especially in the field of gene technology, China has a unique advantage, especially in China's clinical resources, China's pharmaceutical research and development, and other industries in the entire ecosystem are developing rapidly.

The pan born was founded in 2013. In 2015, the commercialization of genetic testing began in the US in 2020. In this regard, Wang Sizhen explained that this is thanks to the development of genomics technology to a breakthrough point, making it able to land on a large scale to the clinical market to serve cancer patients.

"The demand for clinical diagnosis and treatment has always been there, but the development of technology to a suitable point can truly meet this demand on a large scale. The research and clinical application of cancer genomics in China started late than in the United States, but not too late, and we developed very fast. At the same time, China's big industrial environment has also fully supported the development of this field, including the support of basic research, the whole industrial policy, the speed of reform of industry regulatory policies, and so on. Wang Sizhen said.

At the same time, Wang Sizhen believes that in addition to the policy, there are also the rise of China's economy and the awareness of disease prevention in the whole country in recent years. "The ability to pay for the entire Chinese population has risen very rapidly, and the number of people at their own expense has been liberalized in the past few years. When encountering serious diseases, the cost of treatment will not be saved. From this point, we can see that the scale of the market is growing."

Sustained and rapid development in the next three years

However, Wang Sizhen believes that the current market penetration of cancer early screening in China is still at a very early stage. But the next three to five years of high speed development can be expected, such as the whole market penetration of non-invasive product inspection in 2014 less than 1%, but this year, the market penetration of non-invasive product inspection has exceeded 40%+, this process is only six years, indicating that China's market acceptance of new technology and commercialization of the whole potential is fully highlighted.

"Cancer gene testing industry research shows that the growth rate of the industry in the next three years, the annual compound growth rate is 35%, the confidence of the pan born children is higher than the industry average growth." Wang Sizhen said.

The prospectus shows that in the past 2017-2019 years, the operating income of Pan born children was 101 million yuan, 225 million yuan and 323 million yuan respectively. In the first quarter of 2020, the operating income of Pan born children was 76 million 840 thousand yuan, an increase of 15.3% compared with 66 million 650 thousand yuan in the same period in 2019.

Over the past ten years, a large number of gene industry companies have emerged in China. In the field of cancer gene detection, companies are competing fiercely in the diagnostic market. A week before the successful launch of the pan - son market in the United States, another domestic industry stone company also landed on NASDAQ.

In contrast to the two companies, Huang Fanzhi, a joint investment co founder and head of the medical and health fund, said their development stages, company size and subdivision track are similar, and they all choose to go to the US market. For Pan son, going to the US market is also conducive to the internationalization of the company. Ubiquitous children are not only doing business in the United States, but also have some international goals.

According to the twenty-first Century economic report reporter, before the pan son landed in the US capital market, Dr. Hu Yun Fu, a senior FDA expert, officially became the chief medical officer of Pan son, which will lead the company to register and supervise regulatory affairs and drug research and development services in vitro.

From the perspective of business layout, pan children currently focus on three aspects: diagnosis and monitoring, early screening of cancer and service of pharmaceutical enterprises. At least, they have collaborate with hundreds of hospitals and dozens of biopharmaceutical companies and research institutes in the country, so as to meet the needs of partners in genome research, clinical testing and drug diagnosis. Hu Yunfu's accession will play a direct role in promoting the development of products, especially in the future strategic planning.

According to the introduction, at present, the diagnosis of lung cancer is the core of the product. Lung cancer has approved 8 gene detection kits. Follow-up thyroid cancer, nucleic acid kits and other related products will also be listed. The early screening products of liver cancer are also promoting registration.

According to Huang Fanzhi analysis, ubiquitous children focus on precision medical field. In the past, they focused mainly on gene detection of tumors. In the future, they may not be limited to the field of gene, and not only for tumors, but also for more diseases.

?